DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Dexcom has achieved revenues of $4.66bn in 2025 and beat analysts’ consensus for Q4 performance amid a strong demand for its continuous glucose monitoring (CGM) systems. Yet its 2026 outlook was lower ...

Here's a look at the details in the report. The Details: DexCom reported quarterly earnings of 68 cents per share, which beat the Street estimate of 65 cents, according to data from Benzinga Pro.

The accompanying press release dated July 30, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...